Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$14.80
-1.9%
$0.00
$11.06
$63.00
$289.34M1.5224,749 shs53,379 shs
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$0.56
-3.7%
$0.58
$0.16
$0.82
$602.77M0.251.24 million shs679,808 shs
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
$1.33
+12.7%
$1.04
$0.81
$1.76
$31.57M0.79130,291 shs209,600 shs
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
$1.71
+0.2%
$1.71
$1.40
$7.88
$76.08M1.56338,557 shs47,093 shs
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$1.73
+1.8%
$1.81
$1.32
$2.72
$252.65M1.71190,868 shs49,601 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-1.31%-6.56%-98.03%-98.03%-98.03%
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
-5.32%-12.67%+1.03%+44.33%+214.65%
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-2.48%+5.36%+21.98%+28.26%-11.94%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
+0.59%-1.16%0.00%+12.50%-66.86%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
+1.19%+3.03%-8.60%+13.33%-13.27%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
3.2734 of 5 stars
3.80.00.03.72.41.70.6
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.603 of 5 stars
0.03.00.00.03.10.80.0
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
3.1658 of 5 stars
3.75.00.00.00.00.80.6
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
1.2858 of 5 stars
2.02.00.00.00.62.51.3
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
0.9824 of 5 stars
3.51.00.00.00.60.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
3.67
Strong Buy$25.0068.92% Upside
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.00
N/AN/AN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
3.33
Buy$10.00651.88% Upside
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
2.00
Hold$2.0016.69% Upside
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.00
Buy$7.00304.62% Upside

Current Analyst Ratings Breakdown

Latest CBIO, ENLV, ELTP, EPIX, and IMMP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$28.00
6/20/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/18/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$22.00
4/21/2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$10K28,934.00N/AN/A$8.24 per share1.80
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$84.04M7.17$0.02 per share36.08$0.05 per share11.28
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/A$1.00 per shareN/A
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/AN/AN/AN/A$2.81 per shareN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$5.14M49.15N/AN/A$1.05 per share1.65
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-$37.88M-$46.00N/AN/AN/AN/A-293.92%-206.20%N/A
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
-$4.32MN/A0.00N/A-5.13%3.96%2.13%8/14/2025 (Estimated)
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-$15.01M-$0.66N/AN/AN/AN/A-57.67%-50.52%8/29/2025 (Estimated)
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$28.54M-$0.63N/AN/AN/AN/A-23.48%-22.86%8/4/2025 (Estimated)
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
-$28.01MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)

Latest CBIO, ENLV, ELTP, EPIX, and IMMP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q3 2025
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$0.2430N/AN/AN/AN/AN/A
6/30/2025Q4 2025
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
N/A$0.01N/A$0.02N/A$32.00 million
5/30/2025Q1 2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-$0.16-$0.15+$0.01-$0.15N/AN/A
5/8/2025Q2 2025
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$0.19-$0.14+$0.05-$0.14N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/AN/AN/AN/AN/A
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
N/AN/AN/AN/AN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/AN/A
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/AN/AN/AN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/A
2.29
2.29
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.08
4.88
3.50
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/A
7.20
7.20
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/A
67.15
67.15
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/A
18.86
N/A

Institutional Ownership

CompanyInstitutional Ownership
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
75.19%
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.01%
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
1.02%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
75.12%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2.32%

Insider Ownership

CompanyInsider Ownership
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
8.70%
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
14.42%
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
12.28%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
15.50%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
5019.55 million17.85 millionNo Data
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
401.07 billion914.31 millionNot Optionable
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
7023.65 million20.75 millionOptionable
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
5044.39 million37.51 millionOptionable
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2,021146.04 million141.56 millionOptionable

Recent News About These Companies

Immutep Quarterly Activities Report Q3 FY25
Immutep to Participate in Upcoming Investor Conferences
Immutep to Engage in Key Investor Conferences

New MarketBeat Followers Over Time

Media Sentiment Over Time

Crescent Biopharma stock logo

Crescent Biopharma NASDAQ:CBIO

$14.80 -0.29 (-1.92%)
As of 02:31 PM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Elite Pharmaceuticals stock logo

Elite Pharmaceuticals OTCMKTS:ELTP

$0.56 -0.02 (-3.72%)
As of 02:18 PM Eastern

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. Elite Pharmaceuticals, Inc. was incorporated in 1997 and is headquartered in Northvale, New Jersey.

Enlivex Therapeutics stock logo

Enlivex Therapeutics NASDAQ:ENLV

$1.33 +0.15 (+12.71%)
As of 02:50 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

ESSA Pharma stock logo

ESSA Pharma NASDAQ:EPIX

$1.71 +0.00 (+0.23%)
As of 02:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Prima BioMed stock logo

Prima BioMed NASDAQ:IMMP

$1.73 +0.03 (+1.76%)
As of 02:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.